Mesenchymal stromal cells (MSCs)

• Verfasst von: Bieback, Karen [VerfasserIn]
• Verfasst von: Wuchter, Patrick [VerfasserIn]
• Verfasst von: Klüter, Harald [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Titel: Mesenchymal stromal cells (MSCs)
• Titelzusatz: science and f(r)iction
• Verf.angabe: Karen Bieback, Patrick Wuchter, Daniel Besser, Werner Franke, Matthias Becker, Michael Ott, Martin Pacher, Nan Ma, Christof Stamm, Harald Klüter, Albrecht Müller, Anthony D. Ho for the START-MSC consortium
• Jahr: 2012
• Umfang: 10 S.
• Fussnoten: Published online: 31 May 2012 ; Gesehen am 25.06.2018
• Titel Quelle: Enthalten in: Journal of molecular medicine
• Ort Quelle: Berlin : Springer, 1922
• Jahr Quelle: 2012
• Band/Heft Quelle: 90(2012), 7, Seite 773-782
• ISSN Quelle: 1432-1440
• DOI: doi:10.1007/s00109-012-0915-y
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1576815757

Abstract

Due to their multi-lineage differentiation capacity, support of haematopoiesis, immunomodulation and secretion of proregenerative factors, mesenchymal stem/stromal cells (MSCs) are in the focus of intense research since decades. The literature is replete with reports on their potential in preclinical model systems. However, the heterogeneity of the primary cell population as starting material and the diverse protocols for isolation and cultivation are hampering progress in their clinical application. Consensus on common standards and harmonised isolation and characterisation protocols are important to ensure safety and efficacy. This review focuses on the recent scientific evidence of clinically relevant properties and on the speculative cardiomyogenic and hepatic differentiation potential of MSCs. Special emphasis is put on the importance of standardisation and harmonisation in clinical-scale manufacturing.